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Introduction: A survey on cryptococcosis is being conducted regularly in Colombia since 1997. We 
present hereby the results corresponding to patients diagnosed from 2006 to 2010. 
Objective: To analyze the data obtained during this period.
Materials and methods: Retrospective analysis of the corresponding surveys.
Results: A total of 526 surveys originating from 72% of the Colombian political divisions were received 
during the 5-year period. Most patients (76.6%) were males and 74.9% were 21-50 years old. The 
most prevalent risk factor was HIV infection (83.5%) with cryptococcosis defining AIDS in 23% of 
the cases. In the general population the estimated mean annual incidence rate for cryptococcosis 
was 2.4 x 106 inhabitants while in AIDS patients this rate rose to 3.3 x 103. In 474 surveys stating 
clinical features, most frequent complaints were headache 84.5%, fever 63.4%, nausea and vomiting 
57.5%, mental alterations 46.3%, meningeal signs 33.0%, cough 26.4% and visual alterations 24.5%. 
Neurocryptococcosis was recorded in 81.8% of the cases. Laboratory diagnosis was based on direct 
examination, culture and latex in 29.3% cases. From 413 Cryptococcus isolates analyzed, 95.6% 
were identified as C. neoformans var. grubii, 1% C. neoformans var. neoformans, and 3.4% C. gattii. 
Treatment was reported for 71.6% of the cases with amphotericin B alone or in combination with 
fluconazole prescribed in 28%. 
Conclusions: Surveys done through passive surveillance continue to be sentinel markers for HIV 
infection and represent a systematic approach to the study of opportunistic problems regularly afflicting 
AIDS patients since cryptococcosis requires no compulsory notification in Colombia.
Key words: Cryptococcosis, Cryptococcus neoformans, Cryptococcus gattii, acquired immunodeficiency 
syndrome, morbidity, mortality, Colombia
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Criptococosis en Colombia: resultados de la encuesta nacional, 2006-2010
Introducción. Desde 1997 se viene realizando un programa nacional de vigilancia sobre la criptococosis 
en Colombia. Se presentan los resultados correspondientes a los pacientes diagnosticados entre el 
2006 y el 2010.
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Objetivo. Analizar los datos obtenidos durante este periodo.
Materiales y métodos. Análisis retrospectivo de las encuestas.
Resultados. Durante los cinco años mencionados se recibieron 526 encuestas representativas del 
72 % de la división política colombiana. La mayoría de pacientes (76,6 %) eran hombres y 74,9 % 
estaban entre los 21 y los 50 años. El factor de riesgo prevalente fue la infección por VIH (83,5 %), 
y la criptococosis definió el sida en 23 % de los casos. La incidencia anual promedio en la población 
general fue de 2,4 por un millón de habitantes mientras que, en pacientes con sida, aumentó a 3,3 
por 1.000. En 474 encuestas se informaron manifestaciones clínicas; las más frecuentes fueron: 
cefalea (84,5 %), fiebre (63,4 %), náuseas y vómito (57,5 %), alteraciones mentales (46,3 %), signos 
meníngeos (33 %), tos (26,4 %) y alteraciones visuales (24,5 %). La neurocriptococosis se reportó en 
81,8 % de los casos. El diagnóstico se hizo por examen directo, cultivo y antigenemia en 29,3 % de los 
casos. De 413 aislamientos recuperados, 95,6 % fueron C. neoformans var. grubii, 1 % C. neoformans 
var. neoformans, y 3,4 % C. gattii. En 71,6 % de los casos para el tratamiento se administró anfotericina 
B y en 28 % se combinó con fluconazol. 
Conclusiones. La vigilancia pasiva continúa siendo un marcador centinela para la infección por VIH, y 
constituye una aproximación sistemática al estudio de infecciones oportunistas en pacientes con sida, 
debido a que la criptococosis no es de notificación obligatoria en Colombia. 
Palabras clave: criptococosis, Cryptococcus neoformans, Cryptococcus gattii, síndrome de inmuno-
deficiencia adquirida, morbilidad, mortalidad, Colombia
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Cryptococcosis, an opportunistic mycosis affecting 
both immunosuppressed and immunocompetent 
patients, is acquired by the inhalation of the fungal 
propagules, small capsulated yeasts and probably 
also basidiospores, present in the environment (1). 
At present, the etiological agent is classified in 
the Cryptococcus neoformans/Cryptococcus gattii 
species complex, with two species and several 
hybrids: C. neoformans var. grubii, serotype A, C. 
neoformans var. neoformans, serotype D, C. gattii, 
serotypes B and C and the hybrids AD, BD, AA, 
and AB (2-5).
Although it is known that both species affect 
primarily the lungs and secondarily the central 
nervous system (CNS), there are certain differences 
in the epidemiology and clinical presentation of the 
diseases. C. neoformans var. grubii is responsible 
of almost all the infections in AIDS patients whilst C. 
gattii affects mainly apparently immunocompetent 
persons (6). Both C. neoformans and C. gattii invade 
essentially the cerebral parenchyma; however, 
C. gattii is more likely to produce pulmonary and 
cerebral masses (cryptococcomas) (6). 
Since 1981, as a consequence of the AIDS 
epidemic and other type of immunosuppression 
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conditions, infections caused by the members of 
the C. neoformans complex have become important 
causes of morbid-mortality with approximately 
5-10% of the patients with CD4+ lymphopenia 
developing cryptococcosis (7). At present, this 
mycosis is classified among the three most important 
opportunistic infections leading to death in AIDS 
patients (8). The prevalence of the disease in these 
patients has diminished thanks to the introduction 
of the Highly Active Antiretroviral Therapy (HAART) 
but the viral disease is still epidemic in Africa and 
Southeast Asia, where nearly 30% of the patients 
with AIDS are affected by cryptococcosis (8,9).
Even though in Colombia cryptococcosis does 
not require compulsory notification, a series of 
reports reveal its importance in the country (10-
15). In the year 1997, a national survey centered 
in cryptococcosis was designed with the aim of 
identifying the demographic characteristics of the 
afflicted Colombian population, the risk factors 
involved, the laboratory assays employed for 
diagnosis, the etiological agents involved, and the 
initial treatment given to the patients (16). Recently, 
an update on the survey’s questionnaire was done, 
in which, additional to the data already mentioned, 
the person in charge of filling the survey specified 
what type of cryptococcosis was diagnosed and 
what were the results of the therapy given to the 
patients (see supplement 1). 
The aim of this work was to analysis the results 
obtained during the cryptococcosis national survey 





This was a descriptive observational study in 
which clinical and epidemiological information on 
cryptococcosis cases was gathered from the survey 
done during the period 2006-2010. The survey was 
designed according to the guidelines established by 
the European Confederation of Medical Mycology, 
with the corresponding authorization (17); the 
formularies were filled out by health professionals in 
public, private and educational institutions, as well 
as in public health laboratories across the country.
In the survey, the following entries were considered: 
patients demographic data, gender and age, 
year and geographic department of birth, place 
of residence, risk factors (HIV infection, use of 
corticosteroids, autoimmune disease, transplants, 
solid tumor, hematological malignancy, diabetes 
mellitus, hepatic cirrhosis, renal failure, sarcoidosis). 
We inquired if cryptococcosis was an AIDS defining 
illness, we asked about diagnosis date, clinical 
manifestations of the disease, condition of the 
patient when leaving the health center and type of 
clinical treatment. The diagnostic tests employed 
were also registered taking into consideration fungal 
visualization and culture test results, determination 
of the capsular antigen in CSF or sera, and data 
on the results of the diagnostic images (chest 
X-ray, cerebral images). Information about other 
types of treatment received by the patient (anti-TB, 
antiretroviral) was also requested. 
The surveys and isolates were sent to the study 
coordinating centers (Instituto Nacional de Salud 
in Bogotá and Corporación para Investigaciones 
Biológicas in Medellín) and a database was created 
in the Biolomics software and the analysis was 
done in the statistical program Epiinfo 6.1.
Furthermore, a comparison between the data 
obtained in this study with the information published 
for the 1997-2005 period was also done (16).
Ethical considerations
The present study received the approval of the 
Ethics Committee of the CIB. Its implementation 
was subjected to the principles stated in the Helsinki 
declaration concerning medical research in human 
beings. Due to the descriptive character of the 
study and considering that the research reported 
was exempt of any risk to the subjects whose data 
were employed, an informed consent was not 
obtained. This was in accordance with Resolution 
8430 issued in 1993 by the Ministry of Health of 
Colombia in charge of regulating medical research 
in the country. Furthermore all clinical and para-
clinical procedures employed were those required 
by the consulting physician for the establishment 
of the diagnosis with no extra tests being carried 
out. The authors did not intervene with the patients 
and only processed their samples as ordered by 
the physician in charge.
Case definition
A case was defined when clinical findings compatible 
with cryptococcosis were noticed, as well as when 
one or several of the following laboratory results 
were present: isolation of the fungus from a normally 
sterile site, or from sputum, bronchoalveolar lavage 
and/or skin lesions. Additionally, fungal visualization 
in a CSF direct examination with India ink, or in 
a cutaneous lesion, or in a biopsy, as well as a 
capsular antigen titer ≥ 8 in sera or any titer in CSF, 
were considered diagnostic tests.
Patients with relapsing disease were also included 
in the survey if the new clinical episode had occurred 
6 or more months after the initial diagnosis (16). 
Epidemiological analysis
For the analysis, the country was divided in 7 
geographic regions, as follows: 1. Bogotá D.C., 
Cundinamarca and Boyacá; 2. Antioquia and 
Eje Cafetero (Caldas, Risaralda, Quindío); 3. 
Costa Pacífica (Chocó, Valle, Cauca, Nariño); 4. 
Santanderes (Santander, Norte de Santander); 5. 
Tolima and Huila; 6. Costa Caribe and Insular Territory 
(Cesar, La Guajira, Magdalena, Atlántico, Bolívar, 
Sucre, Córdoba and San Andrés y Providencia) 
and 7. Amazonia-Orinoquia (Amazonas, Vaupés, 
Guainía, Putumayo, Caquetá, Meta, Casanare, 
Arauca and Vichada). The geographic origin of 
each patient was determined on the basis of his 
(her) place of residence. 
Cryptococcosis incidence average per annum was 
determined by using the population perspectives 
for the year 2008, the intermediate year of the 
epidemiological survey presented in this study 
(18). The mean incidence rate of cryptococcosis 
per annum in the general population was 
calculated using as denominator the total number 
(43,926,034) of Colombia inhabitants for the year 
2008. Additionally, data on the AIDS cases was 
obtained from the Instituto Nacional de Salud (19); 
the denominator used in this case was 25,122 




The identity of the isolates submitted to the central 
laboratories was confirmed using conventional 
laboratory techniques (20). Species was 
determined employing culture in Canavanine-
Glycine-Bromothymol Blue agar (CGB) (21). The 
isolates were maintained in sterile distilled water 
and as glycerol stocks at -70 °C.
Antifungal susceptibility
These data are part of the ARTEMIS DISC 
Network, Global Program of the antifungal 
susceptibility of which the CIB participates. From 
2006-2009, the susceptibility profile of 135 and 
115 isolates to fluconazole (FCZ) and voriconazole 
(VCZ), respectively, was studied using the disc 
diffusion method M44-A, described by the Clinical 
Laboratory Standards Institute (CLSI) (22). This 
method uses discs of 25 µg/ml of FCZ and 1 µg/
ml of VCZ (Becton Dickinson, Spark, MD). Reading 
of the plates was done using BIOMIC, a Petri 
dish scanner with a digital image analyzer, which 
measures the inhibition millimeters and converts it 
into MIC using a regression curve (Giles Scientific, 
1999, Santa Bárbara, CA). 
Quality control was done with Candida albicans 
ATCC 90028 that shows an inhibition range 
between 32-43 mm. The results of the inhibition 
zones, susceptibility, MIC values and quality control 
data were digitally stored. Even though there are 
no precise criteria about the cutoff point and the 
interpretation for FCZ and VCZ in C. neoformans, 
we used the criteria published by CLSI and Barry 
et al (22,23) for Candida. Isolates susceptible to 
FCZ, had a MIC ≤ 8 µg/ml (< 19 mm inhibition), 
susceptible dose dependent (SDD) between 16-32 
µg/ml (15-18 mm inhibition) and resistant, MIC ≥ 64 
µg/ml (≤ 14 mm inhibition). As for VCZ, susceptible, 
MIC ≤ 1 µg/ml (< 17 mm inhibition), SDD 2 µg/ml 
(14-16 mm inhibition) and resistant, MIC ≥ 4 µg/ml 
(≤ 13 mm inhibition).
Results
During the 5 years of the study, 526 surveys 
were received from 55 institutions located in 22 
Departments (Colombia´ s political divisions) and 
Bogotá, the capital city. The number of surveys 
submitted according to the year was as follows: 115 
(21.9%) in 2006; 111 (21.1%) in 2007; 63 (12.0%) 
in 2008; 128 (24.3%) in 2009 and 109 (20.7%) in 
2010. No surveys were received from La Guajira, 
Magdalena, Bolivar, Sucre, San Andrés and 
Providencia, Vaupés, Guaviare or Vichada. 
Incidence
In the general population data obtained from 
the 5 years of study showed an estimated mean 
annual incidence rate for cryptococcosis of 2.4 x 
106 inhabitants while in AIDS patients this rate rose 
to 3.3 x 103 (Table 1). The estimated mean annual 
incidence for each geographic region in which the 
country was divided is shown in supplement 2. 
Characteristics analyzed
Table 2 summarizes the chosen patient’s 
characteristics, namely, demographic data, risk 
factors, clinical features, clinical presentation, 
diagnostic images, laboratory diagnosis, crypto-
coccal species, varieties and serotypes according 
to the HIV status, and treatment.
In addition, distribution of cryptococcosis patients 
by age according to gender is presented in figure 
1. Clinical features according to AIDS status are 
shown in figure 2. 
Circulating antigen determination
Antigen was determined in 164 CSF samples, with 
a global reactivity of 97.0%, as well as in 66 sera 
samples with reactivity of 90.9%. In AIDS patients 
CSF samples, titers oscillated from 1:1 to 1:8,192. 
In non AIDS patients, such titers ranged from 1:1 to 
1:2,048. Concerning sera, titers were up to 1:1400 
in AIDS - and 1:1,024 in non AIDS – patients
Antifungal susceptibility
Susceptibility data of the isolates studied is shown 
in table 3. 
CD4+ Values. CD4+ count was informed in 104 
(25.4%) surveys out of the 409 patients with AIDS; 
values fluctuated between 2 and 1400 cells/mm3, 
with a media of 52.9 cells/mm3; 87/102 (85.3%) 
patients had values equal or less than 200 cells/
mm3, and from these 75/87 (86.2%) had values 
equivalent or less than 100 cells/mm3. 
Table 1. Cryptococcosis National Survey, 2006-2010. Incidence 
per year
Year Population Cases Incidence/year
  n (%)* /1,000,000
2006 43,405,956 115  (21.9) 2.6
2007 43,926,929 111  (21.1) 2.5
2008 44,451,147 63  (12.0) 1.4
2009 44,978,832 128  (24.3) 2.8
2010 45,509,584 109  (20.7) 2.4
*Total number of surveys received (n=526)
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Table 2. Cryptococcosis in Colombia. Results of the National Surveillance, 2006-2010 in n=526
Data collected or analyzed n %
Demographic data  
Gender 526 100.0
Male 403 76.6
Female  123 23.4
Male:female ratio 3.3:1 
Risk factors 490 93.2
HIV infection males 330 (80.7%); AIDS defining illness 94 (23%)  409 83.5
Autoimmune disease 19 3.9
Corticosteroids 6 1.2
Solid tumor  6 1.2
Other (transplants, diabetes, renal failure, viral and TB meningitis, and lymphoma) 13 2.7
Unknown  37 7.6
Clinical features 474 90.1
Headache 401 84.5
Fever 301 63.4
Nausea and vomiting  273 57.5
Mental alterations  219 46.3
Meningeal signs  156 33.0
Cough  125 26.4
Visual alterations  116 24.5
Neurological signs 129 24.5
Neck stiffness 21 16.3
Intracranial hypertension with no hydrocephalus 26 20.2
Clinical presentation 526 100.0
Neurocryptococcosis  428 81.4
Disseminated cryptococcosis  74 14.1
Pulmonary cryptococcosis 16 3.0
Cryptococcal skin lesions 1 0.2
Neurocryptococcosis + pulmonary cryptococcosis  7 1.3
Diagnostic images
Chest X-ray results 226 43.0
Normal  133 58.8
Abnormal (infiltrates, calcifications, cavitations, multiple nodular lesions)  93 41.2
CT scans and cerebral MRI 130 24.7
Normal  65 50.0
Abnormal (edema, hydrocephaly, adenopathies, minor cerebral atrophy and cryptococcomas ) 65 50.0
Diagnosis based on 526 100.0
Direct examination, culture and latex cryptococcal capsular test 154 29.3
Direct examination, and culture  274 52.1
Direct examination  6 1.1
CSF Cryptococcus isolation in culture 56 10.6
Culture other samples (blood samples, bronchoalveolar lavage, urine, skin)  26 4.9
Latex sera  5 1.0
CSF Cryptococcus isolation in culture 5 1.0
Species, varieties and serotypes non HIV patients 91 77.7
C. neoformans var. grubii serotype A  79 86.8
C. neoformans var. neoformans serotype D  1 1.1
C. gattii  11 12.1
Species, varieties and serotypes HIV patients 324 79.2
C. neoformans var. grubii serotype A  318 98.2
C. neoformans var. neoformans serotype D 3 0.9
C. gattii 3 0.9
Treatment-patients receiving only one antifungal agent 272 51.7
Amphotericin B 237 87.1
Fluconazole 29 10.7
Itraconazole 3 1.1
5-fluorocitosine  2 0.7
Voriconazole  1 0.4
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Relapses. Relapses were informed in 32 
(0.06%) patient surveys. From these, 28 (87.5%) 
corresponded to HIV positive patients. 
Mortality. Data were reported in 40 patient surveys 
at the time of diagnosis. Thirteen out of these 40 
patients (32.5%) corresponded to females and 27 
(67.5%) to males. From these, a total of 28 (70%) 
were HIV positive patients.
Data comparison between present survey and 
the 1997-2005 period. The most relevant data 
are described in table 4. Statistically significant 
differences were observed in the male: female 
ratio, which changed from 7.3:1 in 1997-2005 to 
3.3:1 in 2006-2010.
Discussion
The most important issue being highlighted by 
this study, is the high cryptococcocal morbidity in 
Colombia both in immunocompetent, as well as in 
immunosuppressed populations, illustrating that 
although advances in the antiretroviral therapy have 
occurred, cryptococcosis is still being diagnosed in 
Colombia and several other countries(16,24-27).
In Colombia, the mean annual incidence of 
cryptococcosis is low compared with the reported 
in other regions of the world. In Houston, USA, the 
mean annual incidence reported for the year 2000 
was of 0.4 cases per 100,000 inhabitants (28). In 
Africa, the incidence is even higher: 15.6/100,000 
revealing the heavy disease burden due to 
cryptococcosis (29). In regions like the Northern 
Territory in Australia, it has been reported that 
the mean annual incidence per million population 
was 6.6 and in New Zealand, of 2.2 (30), similar 
to the incidence reported in Colombia. The low 
incidence observed in HIV patients is consistent 
with reports describing the changing epidemiology 
of opportunistic infections in persons with AIDS 
(31). The fact that in Colombia the overall incidence 
of cryptococcosis among HIV patients has not 
changed significantly since 1997 may well be due 
to modifications in the management of HIV infection 
itself rather than to changes in environmental 
exposure to the fungus or to an increase in the 
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Figure 1. Cryptococcosis National Survey, 2006-2010. 
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Figure 2. Cryptococcosis National Survey, 2006-2010. Clinical 
features in AIDS and non AIDS cases. Information based on 469 
surveys.
Table 3. Cryptococcosis National Survey, 2006-2010. Minimal inhibitory concentration (MIC) for fluconazole and voriconazole of 
clinical isolates of the C. neoformans/C. gattii species complex 
                                                      Interpretation1 
Antifungal agent n Susceptible SDD2 Resistant 
   n (%)
Fluconazole 135 87  (64.5) 30  (22.2) 18  (13.3)
Voriconazole 115 110  (96.0) 3  (2.3) 2  (1.7)
1 CLSI criteria
FCZ susceptible (≤8 µg/ml), SDD (16-32 µg/ml), resistant (≥64 µg/ml) 
VCZ susceptible (<1 µg/ml), SDD (2 µg/ml) and resistant (>4 µg/ml)
2 Susceptible dose dependent
392
Biomédica 2012;32:386-98
A predisposition of the male gender to develop 
cryptococcosis, especially in the HIV infected 
population, here was noticed with a clear tendency 
towards presentation of the viral immunosuppression 
in males, a finding that correlates with the 
worldwide situation revealing that this disease 
is more common and more severe in young men 
(25,32-34). Nevertheless, because of the tendency 
of “feminization” of AIDS, this situation is presently 
changing (35), as observed when comparing our 
2006-2010 period results with those obtained 
earlier (1997-2005) with a statistically significant 
difference in the proportion of women infected with 
cryptococcosis whose risk factor was AIDS (3.3:1 
vs. 7.3:1). This observation was accompanied by 
a decrease in the male: female ratio, revealing the 
epidemiological situation of AIDS in Colombia in 
accordance with the reports of an increase in the 
proportion of women with this illness in our country 
(16,19). 
When analyzing the data obtained for the period 
2006-2010, it was observed that cryptococcosis 
is seen in all ages, even in the boundaries of 
life; between them we found 2 patients less than 
15 years of age, which is in agreement with the 
low proportion of children known to develop 
cryptococcosis in global reports, even in endemic 
areas for this disease, except Brazil, where the 
prevalence in children is higher (19,9%) (16,36-39). 
Clinical manifestations such as headache, mental 
alterations and fever, reported in the surveys 
analyzed in this study are similar to those informed 
worldwide for cryptococcosis associated with AIDS 
(34,35) and similar to the findings observed in the 
1997-2005 period in Colombia, where 93.3% of all 
cases showed neurological signs (16). Interestingly 
data from British Columbia revealed that only 
18.3% of the immunocompetent patients affected 
by C. gattii have had CNS involvement with most 
cases revealing pulmonary affection (40). 
It is known that direct examination of the sample 
with India ink is a highly sensitive technique for 
detection of the blastoconidia, facilitating diagnosis 
of the infection. Association with culture increases 
the possibilities of correctly identifying the etiological 
agent, which is rather important for doing an on 
time diagnosis of the disease (41-45). We found 
a high positivity of direct examination and culture 
for the diagnosis of cryptococcosis (81.4%), which 
may imply that these two techniques must be done 
regularly in samples recovered from patients who are 
suspicious of having an inflammatory CNS illness.
We were able to study 413 isolates from the total 
of surveys received, the majority of them recovered 
from AIDS patients, similar to what was reported in 
different parts of the world, where the greater number 
of cryptococcosis cases in immunosuppressed 
patients is associated with C. neoformans var. 
grubii (16,24,25,34). Even though cryptococcosis in 
patients with impaired immunity is rarely caused by 
serotype B, in this study we found 2 patients with 
AIDS, and in the period 1997-2005, 1 of the 30 cases 
caused by C. gattii had HIV infection (16). Infections 
caused by both species of the C. neoformans/C. gattii 
species complex exhibit differences concerning their 
clinical presentation, among others; it is known that 
C. gattii invades the parenchyma more often than 
C. neoformans, and that in patients infected by C. 
gattii pulmonary infections are more common (5,30). 
However, in this study, clinical manifestations were 
similar in the cases attributed to either one of the 2 
species, as observed in the period of time previously 
analyzed (16).
We found a relatively high percentage of isolates 
resistant to FCZ, similar to what was found by 
Pappalardo et al., who have reported a proportion 
of FCZ resistance equal to 12% in Brazil. This same 
author mentions several hypotheses to explain 
the existence of resistant phenotypes that may 
contribute to therapeutic failures (35). However, it is 
important to highlight that since there is no reference 
Table 4. Cryptococcosis National Survey, 2006-2010. Comparison 




Surveys received (n) 931 519
Mean annual incidence, general 
population (x 1,000,000) 2.4 2.4
Mean annual incidence, HIV patients 
(x 1,000) 3.0 3.3
Demographic data 
Male (%) 82.7 76.6
Male:female (AIDS) 7.3:1 3.3:1
Risk factors (%)
HIV infection as risk factor 78.1 83.5
Cryptococcosis AIDS defining illness 24.6 24.9




Headache  85.2 84.5
Nausea and vomiting 59.1 57.5




method for the determination of susceptibility tests for 
this pathogen, and because of the lack of studies that 
correlate clinical prognosis to yeast sensitivity, there is 
inconsistent data concerning therapeutic failure and 
presence of in-vitro resistant strains. Clinical condition 
of patients after treatment could not be ascertained 
from our results since this survey was intended to be 
completed giving only punctual information rather than 
more complete monitoring of the patient´s outcome 
after treatment had been initiated. 
An important finding was that in those patients 
were CD4+ values were informed, 73.5% of these 
had levels equal or less than 100 cells/mm3; this is 
in accordance to the findings reported by Lizarazo 
et. al, who suggested that patients with low CD4+ 
levels represent a population at high risk of acquiring 
cryptococcosis (46). In this group of patients it may 
be useful to have a Point of Care Tests that may 
allow an early diagnosis of cryptococcosis, such 
as CrAg LFA, which helps to perform the diagnosis 
of infectious diseases in resource-limited settings, 
such as in Colombia (47). 
Cryptococcal disease continues to be an important 
cause of death, with a 24.4% found in this study, 
particularly in HIV patients, showing the delay in 
diagnosis and calling the attention to the need to 
consider cryptococcal infection in the differential 
diagnosis of immunocompromised patients 
presenting with meningitis, pneumonia. On the 
other hand there is a need of notifying this and other 
events to the Colombian Public Health Surveillance 
System (SIVIGILA). 
This survey represents an approximation to the real 
situation of cryptococcosis in Colombia. However, 
it has limitations due to the fact that it is a passive 
and voluntary assessment, for that reason it would 
require an audit to confirm the real number of cases 
of cryptococcosis in the participating institutions 
during the surveillance period. This determination 
is still pending at present. 
The time has arrived when we should command 
attention in relation to diseases like AIDS and include 
one of its most important and serious consequences: 
cryptococcosis. Very few complications that may 
be present in advanced status of HIV-AIDS have 
a higher influence in morbidity and mortality than 
cryptococcosis. We are condemned to see very few 
progresses in patients affected by cryptococcosis, 
until we do not compromise by doing a more active 
surveillance so as to offer better treatments, better 
access to diagnostic tests and development of new 
research fields.
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Supplement 1. Colombian national survey on cryptococcosis
Sí No No dato
1. Infección por VIH
Número de células CD4+/mL















12. Sin factor de riesgo aparente
¿Fue la criptococosis la enfermedad que definió el sida?
Diagnóstico de criptococosis
Fecha Día Mes Año Caso nuevo Recaída
Prueba diagnóstica
(si se realizó la prueba, marque con una X el resultado, si no, marque no realizada)
(cuando la respuesta es SI, por favor complete la información)
Positiva Negativa Norealizada
1. Tinta china en el LCR
2. Antígeno capsular en el LCR
Título
3. Antígeno capsular en suero
Título
4. Cultivo para Cryptococcus neoformans







¿De cuál órgano o tejido?
Imágenes diagnósticas (marque con una X la opción que corresponda) Normal Anormal No dato
Radiografía del tórax







Nombre y apellido (iniciales) Sexo M F
Año de nacimiento Nº documento de identidad
Departamento de nacimiento Departamento de residencia Teléfono
ENCUESTA EPIDEMIOLÓGICA SOBRE LA CRIPTOCOCOSIS EN COLOMBIA
INS-CIB El paciente provee consentimiento informado verbal para el diligenciamiento de esta encuesta SI____ NO_____
(cuando la respuesta es SI, por favor complete la información)
Factores de riesgo (marque con una X la opción que corresponda)
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Nota: favor enviar este formulario por correo electrónico a: Patricia Escandón pescandon@ins.gov.co y p_escand@yahoo.com y el aislamiento (especificar de
donde se recuperó) al laboratorio de Micología del Instituto Nacional de Salud, Avenida calle 26 #51-60, Bogotá, Colombia. Teléfono (1) 220 77 00 Ext 1421.
La información recolectada en esta encuesta tendrá un manejo de forma anónima y confidencial.
Imágenes cerebrales diagnósticas ( )marque con una X la opción que corresponda Sí No No dato
1. TAC de cráneo
2. Resonancia magnética (RM) de cerebro
Resultados de los estudios de imágenes cerebrales ( )marque con una X la opción que corresponda
Anormalidad TAC RM Anormalidad TAC RM
1. Masa cerebral 4. Infarto
2. Cerebritis 5. Atrofia cerebral
3. Hidrocefalia 6. Dilatación de los espacios de Virchow-Robin
Manifestaciones clínicas Si No No dato( )marque con una X la opción que corresponda
1. Cefalea
2. Náuseas o vómito
3. Fiebre (temperatura = 38°C)
4. Confusión o cambios mentales
5. Tos (de 3 ó más días de evolución, con o sin expectoración)
6. Pérdida de visión
7. Visión doble
a. Rigidez nucal y signos meníngeos (Kernig y Brudzinski)
b. Hidrocefalia comunicante
c. Hidrocefalia obstructiva
d. Hipertensión intra-craneana sin hidrocefalia
Valor de la presión de apertura del LCR en mm:
B45.0 - J99.8 Criptococosis pulmonar B45.7 Criptococosis diseminada o generalizada
B45.1 - G05.2-G02.1. Criptococosis cerebral,
meningitis, meningocerebral B45.8 Criptococosis especificada NCOP
B45.9 Criptococosis (infección)
Tratamiento para la criptococosis
Medicamentos Dosis/ día Tiempo
Inicial
Mantenimiento 1. 2. 3. 1. 2. 3. 1. 2. 3.
Profilaxis 2°
B45.2 - L99.8. Criptococosis cutánea o de la piel
B45.3 - M90.2. Criptococosis de hueso u ósea
Éxito (vivo)
Falla Recaída Tiempo de recaída
Muerte Tiempo de muerte (tiempo de muerte luego del diagnóstico).





8. Signos neurológicos focales (especificar):
Clasificación de la criptococosis ( )marque con una X la opción que corresponda
Otras terapias
Profesional responsable de la información
Resultado de la terapia (egreso) ( )marque con una X la opción que corresponda
1. 2. 3. 1. 2. 3. 1. 2. 3.
1. 2. 3. 1. 2. 3. 1. 2. 3.
No dato
e. Convulsiones




Convention Geographical region Population
2008
Cases n (%) Incidence/year
/1,000,000
1 Bogotá D.C., Cundinamarca
and Boyacá
10,815,815 109 (20.7) 2.01
2 Antioquia and Eje Cafetero 8,343,642 180 (34.2) 4.2
3 Costa Pacífica 7,657,964 109 (20.7) 2.8
4 Santanderes 3,265,348 42 (8.0) 2.5
5 Tolima and Huila 2,433,326 56 (10.8) 4.7
6 Costa Caribe and Insular
Territory
9,480,026 12 (2.3) 0.3
7 Amazonia -Orinoquia 2,455,026 16 (3.0) 1.3













Supplement 2. Incidence of Cryptococcosis in Colombia according to geographic region. Estimated mean 
annual incidence x 106. Incidence values are shown in circles and region distribution is represented as 
colored numbers and detailed in the table. 
